Abstract

The myelodysplastic syndromes (MDS) are divided into lower-risk and higher-risk categories. This differentiation is important for treatment selection. Over the last decade, we have witnessed significant improvements in the treatment of patients with higher-risk MDS that have resulted in improved survival with the hypomethylating agent 5-azacytidine. This has resulted in a shift from the use of acute myelogenous leukemia (AML)-like therapies, which were traditionally offered to this group of patients...